1 story in the last 7 days
The latest raythera news, distilled by AI into sharp ~100-word summaries. ByteBrief tracks raythera across dozens of tech sources and brings you only what matters, updated hourly. Tap any story for the full brief, or open the original source.

Biogen is acquiring anti-inflammatory drug startup RayThera for up to $1 billion. The deal gives Biogen access to RayThera's pipeline of anti-inflammatory therapies. The acquisition expands Biogen's presence in inflammation and immunology.
Summaries by ByteBrief